PARIS — Azzalure, which is touted as a French rival to Botox, has been approved for sale in the U.K. The muscle relaxant for aesthetic use, which is said to temporarily improve the appearance of moderate to severe vertical lines between the eyebrows, was developed by Ipsen and is commercialized by Galderma, the venture between L’Oréal and Nestlé. Azzalure will be available commercially in the U.K. by the end of the second quarter of this year. The product has gotten the collective nod from 15 European countries’ health authorities.
This story first appeared in the March 19, 2009 issue of WWD. Subscribe Today.